OCGN

Ocugen, Inc.

1.84 USD
-0.08 (-4.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ocugen, Inc. stock is up 48.39% since 30 days ago. The next earnings date is Aug 19, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 May’s closed higher than April. In the last 4 Unusual Options Trades, there were 2 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Mar 14:39 17 May, 2024 2.50 CALL 500 214
05 Apr 14:30 17 Jan, 2025 0.50 CALL 200 5313
22 Apr 13:57 21 Jun, 2024 1.50 PUT 1600 10
01 May 14:42 21 Jun, 2024 1.50 PUT 3000 2474

About Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis. OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD) and OCU200, is in preclinical development stage.

  • Chardan Capital
    Wed May 15, 10:56
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 15, 06:44
    buy
    confirm
  • Chardan Capital
    Mon Apr 22, 07:44
    buy
    confirm